Acid Reducers Do Not Impact VEGF Inhibitor Efficacy in Metastatic RCC

Article

The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study.

The use of proton pump inhibitors (PPIs) does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma (mRCC), according to a new study.

“PPIs are potent suppressors of gastric acid secretions,” said Aly-Khan Lalani, MD, of the Dana-Farber Cancer Institute in Boston, who presented the new study at the 15th International Kidney Cancer Symposium, held November 4–5 in Miami, Florida. “Acid suppressive agents are increasingly prescribed, with use documented in 10% of all ambulatory visits in the United States, and this may be even higher in the oncology setting.”

Because optimal gastric pH appears to play a role in drug exposure of oral VEGF TKIs, Lalani and colleagues conducted a pooled analysis of mRCC patients to see if PPI use has any effect on the drugs’ efficacy. The total cohort included 2,188 mRCC patients treated in phase II and III trials.

There were 120 PPI users included, and 2,068 non-users. There were some baseline differences between those groups; fewer PPI users were younger than 65 years, and more PPI users were male. Most patients in both groups (85.3% of total) had undergone prior nephrectomy, and most patients were IMDC intermediate risk. A total of 952 patients (43.5%) were treated with sunitinib, followed by axitinib (28.6%) and sorafenib (27.9%).

The median overall survival was 24.1 months in PPI users, and 21.4 months in non-users, for a hazard ratio (HR) of 1.051 (95% CI, 0.760–1.435; P = .754). Progression-free survival was also similar, with a median of 5.5 months in PPI users and 8 months in non-users, for an HR of 1.01 (95% CI, 0.79–1.30; P = .902). The response rates were 23.3% and 27.4%, respectively (P = .344), and grade 3/4/5 adverse events were comparable between groups as well.

The results did not differ when patients were stratified by IMDC risk group and by specific agent used.

“We demonstrated that PPI use does not appear to impact the efficacy of oral VEGF TKIs in mRCC,” Lalani concluded. He added, though, that as the use of concomitant medications rises, “the risk of polypharmacy and drug-drug and drug-food interactions will continue to rise.”

Recent Videos
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Related Content